UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 12, 2017
TABULA RASA HEALTHCARE, INC.
(Exact Name of Registrant Specified in Charter)
Delaware |
| 001-37888 |
| 46-5726437 |
(State or Other |
| (Commission File |
| (I.R.S. Employer |
228 Strawbridge Drive, Suite 100 |
|
|
Moorestown, New Jersey |
| 08057 |
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (866) 648-2767
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 8.01. Other Events.
On June 12, 2017, Tabula Rasa HealthCare, Inc. (the “Company”) entered into an amendment to each of the Restricted Stock Grant Agreements (collectively, the “Restricted Stock Grant Agreements”), each dated September 28, 2016, by and between the Company and each of Dr. Calvin H. Knowlton, Chief Executive Officer of the Company, Dr. Orsula V. Knowlton, President of the Company, and Brian W. Adams, Chief Financial Officer of the Company, pursuant to which each of Dr. Calvin Knowlton, Dr. Orsula V. Knowlton and Mr. Adams received a restricted stock award of 337,307, 267,268, and 70,038 shares of the Company’s common stock, respectively, which were scheduled to vest in full on May 31, 2017. Pursuant to the amendments, all shares of restricted stock granted pursuant to the Restricted Stock Grant Agreements will now vest in full on May 31, 2018.
Each of the prior grants was made pursuant to a form grant agreement previously approved by the Company’s Compensation Committee, and all of the aforementioned amendments to the vesting schedules were approved by the Company’s Compensation Committee.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TABULA RASA HEALTHCARE, INC. | |
|
| |
|
| |
| By: | /s/ Dr. Calvin H. Knowlton |
|
| Dr. Calvin H. Knowlton |
|
| Chief Executive Officer |
|
| |
Dated: June 15, 2017 |
| |